No Detail Found!

Frequencies of Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Lean Individuals

Author(s)
Anum Rasheed Department of Medicine, Pakistan Ordinance Factories Hospital,Wah Cantonment,Pakistan
Nauman Ismat Butt Department of Medicine & Allied, Azra Naheed Medical College, Superior University,Lahore,Pakistan
Fawad Yasin Department of Radiology, Pakistan Air Force Hospital,Islamabad,Pakistan
Hira Aslam Department of Medicine, Capital Developmental Hospital,Islamabad,Pakistan
Kanwal Shahid Department of Medicine, Pakistan Ordinance Factories Hospital,Wah Cantonment,Pakistan
Nimra Kanwal Department of Medicine, Agha Khan Medical Services,Gilgit,Pakistan
Abstract
Background: Non-Alcoholic Fatty Liver Disease (NAFLD) prevalence has doubled in the last 20 years and is becoming a vital health concern due to its increasing prevalence. Lean patients having normal-weight central obesity with NAFLD may have increased morbidity and all-cause mortality and thus form an important target for lifestyle modifications and preventive strategies. Objective: To determine frequencies of NAFLD and Metabolic Syndrome in lean individuals. Methods: The present cross-sectional study was undertaken at the Medicine Department, Pakistan Ordinance Factories Hospital, Wah Cantonment Pakistan from July 2018 to June 2020 enrolling 230 patients aged 20 to 70 years, of both sex. Demographic information, co-morbid conditions, BMI, and waist circumference were recorded. An abdominal ultrasound was performed to determine hepatic fatty infiltration. Blood samples were collected for serum HDL-cholesterol (HDL-C) and serum triglyceride estimation. SPSS 22.0 was used for data entry and analysis. Results: Mean age was 45.7+12.5 years with male predominance at 130 (56.5%). Diabetes mellitus was present in 104 (45.2%) and 102 (44.3%) were hypertensive. The mean BMI was 23.4+3.6 kg/m2. The mean serum triglyceride level was 209+10.1 mg/dl and elevated at 141 (61.3%). The mean serum HDL-C level was 23.1+4.2 mg/dl and was reduced by 142 (61.8%). NAFLD was seen in 38 (16.5%) patients and 24 (10.4%) had Metabolic Syndrome. Among the 38 lean NAFLD patients, 21 (55.3%) had Metabolic Syndrome.Conclusion: NAFLD was seen in almost one-fifth of lean patients enrolled. Metabolic syndrome was reported in more than one-half of these lean NAFLD patients
Publication Details
Page(s) 8-13
Published Journal: Liaquat National Journal of Primary Care, Volume: 6, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
Metabolic syndrome, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease (NAFLD), lean patients, hepatic malignancy
References
LaBrecque DR,Abbas Z,Anania F,Ferenci P,Khan AG,Goh KL .2014 .World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol, 48(6) : 467-73.
Hashimoto E,Taniai M .2013 .Tokushige K. Characteristics and diagnosis of NAFLD/NASH. , 28(Suppl 4) : 64-70.
Lee YH,Cho Y,Lee BW,Park CY,Lee DH,Cha BS .2019 .Nonalcoholic fatty liver disease in diabetes. Part I: Epidemiology and diagnosis. Diabetes Metab J, 43(1) : 2Fdmj-45.
El Azeem HA,Khalek el-SA,El-Akabawy H,Naeim H,Khalik HA,Alfi AA .2013 .Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J Saudi Heart Assoc, 07(4) : 239-46.
Wong VW,Wong GL,Tsang SW,Fan T,Chu WC,Woo J .2011 .High prevalence of colorectal neoplasm in patients with nonalcoholic steatohepatitis. Gut, 60(6) : 829-36.
Machado MV,Cortez-Pinto H MV .2012 .Fatty liver in lean patients: is it a diferent disease?. Ann Gastroenterol, 25(1) : 1-2.
Sahakyan KR,Somers VK,Rodriguez-Escudero JP,Hodge DO,Carter RE,Sochor O .2015 .Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med, 163(11) : 2525-35.
Ha Y,Seo N,Shim JH,Kim SY,Park JA,Han S .2015 .Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study. J Gastroenterol Hepatol, 30(11) : 1666-72.
Feldman A,Eder SK,Felder TK,Kedenko L,Paulweber B,Stadlmayr A .2016 .Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. Am J Gastroenterol, 112(1) : 102-10.
Szczepaniak LS,Nurenberg P,Leonard D,Browning JD,Reingold JS,Grundy S .2005 .Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab, 288(2) : E462-8.
Deedwania PC,Hunninghake DB,Bays HE,Jones PH,Cain VA,Blasetto JW .2004 .Efects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol, 09(3) : 360-6.
Lim JU,Lee JH,Kim JS,Hwang YI,Kim TH,Lim SY .2017 .Asia-Pacific body mass index classifications in COPD patients. Int J Chron Obstruct Pulmon Dis, 12 : 2465-75.
Huang PL .2009 .A comprehensive definition for metabolic syndrome. Dis Model Mech, 2(5) : 231-7.
Kim HJ,Kim HJ,Lee KE,Kim DJ,Kim SK,Ahn CW .2004 .Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med, 164(19) : 2169-75.
Bellentani S,Saccoccio G,Masutti F,Crocè LS,Brandi G,Sasso F .2000 .Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med, 132(2) : 200001180-7.
Akbar DH,Kawther AH .2003 .Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care, 26(12) : 3351-2.
Niaz A,Ali Z,Nayyar S,Fatima N. .2011 .Prevalence of NAFLD in healthy and young male individuals. ISRN Gastroenterol, : 2F363546.
Zheng W,McLerran DF,Rolland B,Zhang X,Inoue M,Matsuo K .2011 .Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med, 364(8) : 719-29.
Dela Cruz AC,Bugianesi E,George J,Day CP,Liaquat H,Charatcharoenwitthaya P .2014 .5): S-909. Gastroenterology, 5085(14) : 63307-2.
Zein CO,Unalp A,Colvin R,Liu YC,McCullough AJ .2010 .Nonalcoholic Steatohepatitis Clinical Research Network. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol, 07(4) : 753-9.
Lo L,McLennan SV,Williams PF,Bonner J,Chowdhury S,McCaughan GW .2010 .Diabetes is a progression factor for hepatic ifbrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol, 10(2) : 435-44.
Starley BQ,Calcagno CJ,Harrison SA .2010 .Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology, 51(5) : 1820-32.
Hebbard L,George J .2010 .Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol, 8(1) : 35-44.
Chowdhry MAT,Butt NI,Shakeel H,Gondal MNF,Saeed H. Tahir H MNF .2021 .Is lack of patient knowledge a cause of poorly controlled diabetes mellitus. PJMHS, 15(9) : 2302-4.
Zia N,Aftab S,Butt NI,Ashfaq F,Anser A,Saeed S. .2093 .Prevalence of silent cardiac ischemia in type II diabetes mellitus. Pak Heart J, 54(2) : 162-6.
Afzal H,Butt NI,Ashfaq F,Habib O,Anser A,Aftab S. .2023 .Obstructive sleep apnea in type 2 diabetes mellitus. RMJ, 48(1) : 20-2.
Meo SA,Zia I,Bukhari IA,Arain SA .2016 .Type 2 diabetes mellitus in Pakistan: Current prevalence and future forecast. J Pak Med Assoc, 66(12) : 1637-42.
Radu F,Potcovaru CG,Salmen T,Filip PV,Pop C,FierbințeanuBraticievici C. C .2023 .The link between NAFLD and metabolic syndrome. Diagnostics, 13(4) : 614.
Barale C,Russo I. .2020 .Influence of cardiometabolic risk factors on platelet function. Int J Mol Sci, 21(2) : 623.
Lemieux I,Després JP .2020 .Metabolic syndrome: past, present and future. Nutrients, 12(11) : 3501.
Riazi K,Azhari H,Charette JH,Underwood FE,King JA,Afshar EE .2022 .The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 1253(22) : 00165-0.
Anwar A,Butt NI,Ashfaq F,Aftab S,Nasim H,Khan FA .2022 .Elevated CRP level in metabolic syndrome. RMJ, 47(4) : 837-40.
Jin YJ,Kim KM,Hwang S,Lee SG,Ha TY,Song GW .2012 .Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. J Gastroenterol Hepatol, 07165(8) : 1746-7.
Xu R,Pan J,Zhou W,Ji G,Dang Y. .2022 .Recent advances in lean NAFLD. Biomed Pharmacother, 153 : 113331.
0

Citations

0

Downloads

44

Views